Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2202170 (2022).
Jiang, J. et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl. Lung Cancer Res. 11, 277–294 (2022).
Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021).
Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020).
Pisters, K. M. et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 28, 1843–1849 (2010).
Hellmann, M. D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42–e50 (2014).
Testing new neoadjuvant combos in NSCLC. Cancer Discov. OF1 (2022).
Acknowledgements
The authors thank T. Cascone (The University of Texas MD Anderson Cancer Center) for her expertise and consultation regarding this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.S. has received speaker’s fees from AstraZeneca and Peer View, and consultation fees from AstraZeneca and Medscape. S.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Sepesi, B., Swisher, S.G. Role of neoadjuvant chemoimmunotherapy for resectable NSCLC. Nat Rev Clin Oncol 19, 497–498 (2022). https://doi.org/10.1038/s41571-022-00647-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00647-9
